AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- EVE Health Group finalises Nextract acquisition
- Product development targets $8.1B ED market
- Leadership team expanded for growth phase
EVE Health Group (ASX:EVE) has officially finalised its acquisition of biotechnology innovator Nextract, a strategic milestone that strengthens the company’s presence in the regulated healthcare sector. This development aligns with broader ambitions to deliver value-driven health solutions in the fast-evolving pharmaceuticals landscape.
The acquisition unlocks significant potential in the global erectile dysfunction (ED) market, estimated at AU$8.1 billion. Nextract is currently advancing proprietary oral strip and chewable delivery systems using active pharmaceutical ingredients like Tadalafil—an established therapy in ED treatment—with a focus on rapid onset, aiming for effects within 15 minutes of consumption.
Driving Innovation with Product Development
Stability testing is underway for Nextract’s key candidates, which include treatments not only for ED but also dysmenorrhoea, a condition linked to severe menstrual pain. These tests are critical under pharmaceutical R&D protocols and assess shelf-life and product integrity under varying environmental conditions. The findings will be central to regulatory filings with Australia’s Therapeutic Goods Administration (TGA).
EVE’s expansion into this high-growth niche comes as part of its broader pivot into regulated healthcare—an area of increasing interest for many ASX300 companies seeking to diversify their portfolios.
Strategic Funding and Integration Roadmap
To facilitate the transaction, EVE issued 83.33 million fully paid ordinary shares at a post-consolidation price of $0.036 per share, following shareholder approval in late May. An additional $1 million placement to institutional investors, along with a share purchase plan targeting up to $500,000, will support post-acquisition integration, manufacturing scale-up, and regulatory activities.
These capital moves are structured to ensure minimal disruption while positioning the company for a seamless transition and early-stage growth in its new therapeutic verticals.
Leadership Enhancements for Scaled Execution
With the acquisition now complete, EVE has strengthened its leadership ranks. Dr Stuart Gunzburg, Nextract’s founder, has been appointed chief scientific officer and executive director, bringing deep expertise in pharmaceutical formulation. He will spearhead the company’s innovation and R&D programs. Damian Wood is set to assume the CEO position post-transaction, bringing experience across clinical development, regulatory strategy, and commercial execution.
This move reinforces EVE Health Group’s shift into advanced healthcare delivery while leveraging Nextract’s science-backed pipeline to target tangible market opportunities. With enhanced leadership, a focused therapeutic agenda, and robust regulatory planning, the company is poised for its next phase of growth in the ASX300 landscape.
